Saturday, Oct. 29
15:45 – 16:45 (1 hr)
Meeting Room: Chestnut (Mezzanine)
Wiplove Lamba*, MD, FRCPC; Valerie Primeau, MD, FRCPC
- Medical Expert
- Health Advocate
At the end of this session, participants will be able to: 1) Describe and list the key components of the assessment and treatment for opioid use disorders; 2) Understand and appreciate when harm reduction versus specific opiate agonist treatment would be indicated; and 3) Develop an integrated approach to opioid use disorder and its comorbidities.
Opiate agonist treatment, in the form of methadone and sublingual buprenorphine/naloxone, has historically been managed by primary care physicians with expertise in addiction. Now, with the opioid crisis, psychiatry residency graduates are being trained in opiate agonist treatment. This workshop is an opportunity for psychiatrists in practise to learn the basics of the screening, assessment, and treatment of opioid use disorders. This workshop will be interactive, case-based, and focused through a psychiatry lens. Principles of harm reduction, opioid detoxification, and opioid maintenance treatment will be discussed. Extra emphasis will be placed on the assessment and treatment of psychiatric comorbidities, as well as the value of integrated versus sequential treatment. This will include both pharmacotherapy and psychotherapy. Attendees will receive access to resources and websites that will help them integrate these skills into their practice. In the past, the presenters have been available to guide attendees on developing personalized learning plans to integrate these skills into their practice.
- CRISM. CRISM National Guidelines for the Clinical Management of Opioid Use Disorder. Ottawa (ON): Author; Available from: https://crism.ca/wp-content/uploads/2018/03/CRISM_NationalGuideline_OUD-ENG.pdf
- Bruneau J, Ahamad K, Goyer MÈ, et al. Management of opioid use disorders: a national clinical practice guideline. CMAJ 2018;190:E247–E257.